Silicon Laboratories Q3 2026 revenue rises 22% to $251M
Medical revenue reached a quarterly record as distributor inventories fell to a multi-year low and end-customer inventory was near record lows.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Silicon Laboratories (SLAB) reported third-quarter 2026 revenue of $251 million, up 22% year over year. Industrial & Commercial revenue was $141 million, up 20%, and Home & Life revenue was $110 million, up 24%. GAAP diluted earnings per share was $0.26, compared with a $0.30 loss per share in the year-ago quarter; non-GAAP diluted earnings per share was $1.05, up 228% year over year.
GAAP operating income was $8 million, versus a $12.3 million operating loss a year earlier, and GAAP gross margin was 60.8%. Non-GAAP operating income was $40 million, with a 61.0% gross margin. For the nine months ended October 3, 2026, net cash provided by operating activities was $37.2 million, versus $87.4 million in the prior-year period. Cash and cash equivalents were $423.0 million on October 3, 2026.
Because of the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs suspended forward-looking guidance. Management said current backlog and design-win ramps position the company for continued revenue growth and meaningful earnings expansion.
3 points · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRevenue increased 22% year over year to $251 million.
- Moderate pointNon-GAAP diluted EPS rose 228% to $1.05 year over year.
- Moderate pointGAAP diluted EPS was $0.26, versus a $0.30 loss per share.
Negative
- Moderate pointNine-month operating cash flow was $37.2 million, versus $87.4 million in the prior-year period.
Filing Explained
At October 3, 2026, Silicon Labs reported 33,384 thousand common shares issued and outstanding, versus 32,955 thousand at January 3; the higher outstanding count reduces an existing holder’s percentage ownership absent offsetting changes.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Revenue: $251 million
Industrial & Commercial revenue: $141 million
Home & Life revenue: $110 million
+4 more
7 metrics
Revenue
$251 million
Third quarter 2026; up 22% year over year
Industrial & Commercial revenue
$141 million
Third quarter 2026; up 20% year over year
Home & Life revenue
$110 million
Third quarter 2026; up 24% year over year
GAAP diluted earnings per share
$0.26
Third quarter 2026; compared with a loss of $0.30 in the year-ago quarter
Non-GAAP diluted earnings per share
$1.05
Third quarter 2026; up 228% year over year
Net cash provided by operating activities
$37.2 million
Nine months ended October 3, 2026; compared with $87.4 million in the prior-year period
Cash and cash equivalents
$423.0 million
October 3, 2026
Key Terms
non-GAAP diluted earnings per share, design-win ramps, weighted-average common shares outstanding, deferred revenue and returns liability
4 terms
design-win ramps technical
"current backlog and design-win ramps position us"
deferred revenue and returns liability financial
"Deferred revenue and returns liability"
Earnings Snapshot
Revenue: $251 million · Guidance included
Third quarter ended October 3, 2026
Revenue
$251 million
Up 22% year over year
GAAP diluted earnings per share
$0.26
Compared with a loss of $0.30 in the year-ago quarter
Non-GAAP diluted earnings per share
$1.05
Up 228% year over year
GAAP operating income
$8 million
Compared with a $12.3 million operating loss in the year-ago quarter
Guidance
Silicon Labs suspended forward-looking guidance because of the announced pending acquisition by Texas Instruments.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was SLAB's third-quarter 2026 revenue?
Silicon Laboratories reported $251 million in third-quarter 2026 revenue, up 22% year over year. Industrial & Commercial revenue was $141 million, up 20%, while Home & Life revenue was $110 million, up 24%.
How did SLAB's medical revenue perform in the third quarter of 2026?
Medical revenue reached a new quarterly record, increasing 48% sequentially and more than 300% year over year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 10, 2026
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | ||||
Registrant’s telephone number, including area code: (512 ) 416-8500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. o
Item 2.02. Results of Operations and Financial Condition
On November 10, 2026, Silicon Laboratories Inc. (“Silicon Laboratories”) issued a press release announcing its results of operations for its fiscal quarter ended October 3, 2026. A copy of the press release is attached as Exhibit 99 to this report.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
| 99 | Press Release of Silicon Laboratories Inc. dated November 10, 2026 | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
Use of Non-GAAP Financial Information
From time to time, Silicon Laboratories provides certain non-GAAP financial measures as additional information relating to its operating results. The non-GAAP financial measurements provided in the press release furnished herewith do not replace the presentation of Silicon Laboratories’ GAAP financial results. These additional measurements merely provide supplemental information to assist investors in analyzing Silicon Laboratories’ financial position and results of operations; however, these measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies.
Non-GAAP financial measures used by Silicon Laboratories include non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense and non-GAAP research and development expense as a percentage of revenue, non-GAAP selling, general and administrative expense and non-GAAP selling, general and administrative as a percentage of revenue, non-GAAP operating expenses and non-GAAP operating expenses as a percentage of revenue, non-GAAP operating income (loss) and non-GAAP operating income (loss) as a percentage of revenue, non-GAAP income (loss) before income taxes and equity-method earnings (loss), non-GAAP tax expense, non-GAAP tax rate, non-GAAP net income (loss), and non-GAAP diluted earnings (loss) per share. Silicon Laboratories has chosen to provide this information to investors because it believes that such supplemental information enables them to perform meaningful comparisons of past, present and future operating results, and as a means to highlight the results of core ongoing operations.
Non-GAAP financial measures are adjusted by the following items, as applicable for the relevant period:
•Stock compensation expense – represents charges for employee stock awards issued under Silicon Laboratories’ stock-based compensation plans. Stock compensation expense is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
•Intangible asset amortization – primarily represents charges for the amortization of intangibles assets, such as core and developed technology, customer relationships and trademarks acquired in connection with business combinations. Intangible asset amortization is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
•Merger-related costs – primarily including the following: costs associated with the planned merger with Texas Instruments Incorporated, such as financial advisory, legal, accounting, and other related costs. Merger-related costs are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
•Termination costs, impairments, and fair value and other adjustments – primarily include costs associated with certain employee terminations, asset impairments, fair value adjustments resulting from observable price changes and other non-cash adjustments. Termination costs, impairments, and fair value and other adjustments are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
•Income tax adjustments – effective from the first quarter of 2026, represents the application of a long-term non-GAAP tax rate of 18% to non-GAAP income before income taxes. The non-GAAP tax rate is determined based on a multi-year forecast that takes into consideration the following: the current and
deferred income tax effects of the above non-GAAP adjustments; other indirect impacts of excluding stock-based compensation; and the income tax impact of certain intercompany license arrangements for technology acquired in business combinations. This non-GAAP tax rate also considers factors such as tax structure, tax positions in various jurisdictions, and key legislation in significant jurisdictions where Silicon Laboratories operates. This non-GAAP tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in geographic earnings mix, changes to strategy or business operations, or corporate organizational changes related to acquisitions or tax planning opportunities.
Pursuant to the requirements of Regulation G, Silicon Laboratories has provided in the press release furnished with this report a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. The information contained therein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Silicon Laboratories, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SILICON LABORATORIES INC. | ||||||||
November 10, 2026 | /s/ Dean Butler | |||||||
| Date | Dean Butler | |||||||
| Senior Vice President and Chief Financial Officer | ||||||||
| (Principal Financial Officer) | ||||||||
Exhibit 99
Silicon Labs Reports Third Quarter 2026 Results
Wireless IoT leader delivers $251 million in revenue and strong earnings growth
AUSTIN, Texas – November 10, 2026 – Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the third quarter, which ended October 3, 2026.
“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued,” said Matt Johnson, President and Chief Executive Officer. “Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”
Third Quarter Financial Highlights
•Revenue was $251 million, up 22% year-over-year
•Industrial & Commercial revenue was $141 million, up 20% year-over-year
•Home & Life revenue was $110 million, up 24% year-over-year
•Bookings imply a healthy demand environment, while distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter
•Medical revenue reached a new quarterly record, increasing 48% sequentially and more than 300% year-over-year
•GAAP diluted earnings per share was $0.26, compared with a loss of $0.30 in the year-ago quarter
•Non-GAAP diluted earnings per share was $1.05, up 228% over the comparable period last year
Results on a GAAP basis:
•GAAP gross margin was 60.8%
•GAAP operating expenses were $145 million
•GAAP operating income was $8 million
•GAAP diluted earnings per share was $0.26
Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:
•Non-GAAP gross margin was 61.0%
•Non-GAAP operating expenses were $113 million
•Non-GAAP operating income was $40 million
•Non-GAAP diluted earnings per share was $1.05
Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.
About Silicon Labs
Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the
trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at silabs.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Silicon Labs’ current expectations, which are based on its current views and assumptions. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward looking. These forward-looking statements include, but are not necessarily limited to, Silicon Labs’ expectations regarding its near- and long-term strength and continued revenue growth and earnings expansion and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs’ business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs’ distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of public health crises on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs’ products and its networks; risks associated with any material weakness in our internal controls over financial reporting; risks relating to compliance with laws and regulations; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.
Note to editors: Silicon Laboratories, Silicon Labs, the “S” symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
For more information: Silicon Labs Investor Relations, investor.relations@silabs.com
Silicon Laboratories Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| October 3, 2026 | October 4, 2025 | October 3, 2026 | October 4, 2025 | ||||||||||||||||||||
| Revenues | $ | 250,892 | $ | 205,999 | $ | 692,581 | $ | 576,558 | |||||||||||||||
| Cost of revenues | 98,314 | 86,980 | 272,331 | 251,653 | |||||||||||||||||||
| Gross profit | 152,578 | 119,019 | 420,250 | 324,905 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 93,174 | 87,685 | 276,784 | 263,725 | |||||||||||||||||||
| Selling, general and administrative | 51,453 | 43,676 | 163,263 | 128,469 | |||||||||||||||||||
| Operating expenses | 144,627 | 131,361 | 440,047 | 392,194 | |||||||||||||||||||
| Operating income (loss) | 7,951 | (12,342) | (19,797) | (67,289) | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest income and other, net | 3,185 | 3,046 | 9,300 | 10,672 | |||||||||||||||||||
| Interest expense | (226) | (226) | (709) | (761) | |||||||||||||||||||
| Income (loss) before income taxes | 10,910 | (9,522) | (11,206) | (57,378) | |||||||||||||||||||
| Provision for income taxes | 2,059 | 414 | 6,432 | 4,845 | |||||||||||||||||||
| Net income (loss) | $ | 8,851 | $ | (9,936) | $ | (17,638) | $ | (62,223) | |||||||||||||||
| Earnings (loss) per share: | |||||||||||||||||||||||
| Basic | $ | 0.27 | $ | (0.30) | $ | (0.53) | $ | (1.91) | |||||||||||||||
| Diluted | $ | 0.26 | $ | (0.30) | $ | (0.53) | $ | (1.91) | |||||||||||||||
| Weighted-average common shares outstanding: | |||||||||||||||||||||||
| Basic | 33,376 | 32,835 | 33,182 | 32,656 | |||||||||||||||||||
| Diluted | 33,752 | 32,835 | 33,182 | 32,656 | |||||||||||||||||||
Non-GAAP Financial Measurements
In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.
The non-GAAP financial measurements do not replace the presentation of Silicon Labs’ GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs’ financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share data)
| Three Months Ended October 3, 2026 | ||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Income Statement Items | GAAP Measure | GAAP Percent of Revenue | Stock Compensation Expense | Intangible Asset Amortization | Merger-Related Costs | Non-GAAP Measure | Non-GAAP Percent of Revenue | |||||||||||||||||||||||||||||||||||||
| Revenues | $ | 250,892 | ||||||||||||||||||||||||||||||||||||||||||
| Gross profit | 152,578 | 60.8 | % | $ | 459 | $ | — | $ | — | $ | 153,037 | 61.0 | % | |||||||||||||||||||||||||||||||
| Research and development | 93,174 | 37.1 | % | 11,996 | 2,295 | 3,623 | 75,260 | 30.0 | % | |||||||||||||||||||||||||||||||||||
| Selling, general and administrative | 51,453 | 20.5 | % | 10,594 | — | 3,281 | 37,578 | 15.0 | % | |||||||||||||||||||||||||||||||||||
| Operating expenses | 144,627 | 57.6 | % | 22,590 | 2,295 | 6,904 | 112,838 | 45.0 | % | |||||||||||||||||||||||||||||||||||
| Operating income | 7,951 | 3.2 | % | 23,049 | 2,295 | 6,904 | 40,199 | 16.0 | % | |||||||||||||||||||||||||||||||||||
| Three Months Ended October 3, 2026 | ||||||||||||||||||||||||||||||||||||||
| Non-GAAP Earnings Per Share | GAAP Measure | Stock Compensation Expense* | Intangible Asset Amortization* | Merger-Related Costs* | Income Tax Adjustments** | Non- GAAP Measure | ||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 8,851 | $ | 23,049 | $ | 2,295 | $ | 6,904 | $ | (5,710) | $ | 35,389 | ||||||||||||||||||||||||||
| Diluted shares outstanding | 33,752 | 33,752 | ||||||||||||||||||||||||||||||||||||
| Diluted earnings per share | $ | 0.26 | $ | 1.05 | ||||||||||||||||||||||||||||||||||
*Represents pre-tax amounts
** Represents the application of an 18% non-GAAP tax rate
Silicon Laboratories Inc.
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(Unaudited)
| October 3, 2026 | January 3, 2026 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 423,013 | $ | 364,222 | |||||||
| Short-term investments | 16,828 | 79,400 | |||||||||
| Accounts receivable, net | 79,966 | 64,513 | |||||||||
| Inventories | 133,391 | 95,566 | |||||||||
| Prepaid expenses and other current assets | 71,421 | 70,316 | |||||||||
| Total current assets | 724,619 | 674,017 | |||||||||
| Property and equipment, net | 131,687 | 128,643 | |||||||||
| Goodwill | 376,389 | 376,389 | |||||||||
| Other intangible assets, net | 16,246 | 23,130 | |||||||||
| Other assets, net | 87,213 | 67,138 | |||||||||
| Total assets | $ | 1,336,154 | $ | 1,269,317 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 68,860 | $ | 50,717 | |||||||
| Deferred revenue and returns liability | 9,804 | 5,359 | |||||||||
| Other current liabilities | 78,841 | 87,711 | |||||||||
| Total current liabilities | 157,505 | 143,787 | |||||||||
| Other non-current liabilities | 53,267 | 31,112 | |||||||||
| Total liabilities | 210,772 | 174,899 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued | — | — | |||||||||
| Common stock – $0.0001 par value; 250,000 shares authorized; 33,384 and 32,955 shares issued and outstanding at October 3, 2026 and January 3, 2026, respectively | 3 | 3 | |||||||||
| Additional paid-in capital | 206,203 | 157,402 | |||||||||
| Retained earnings | 919,176 | 936,814 | |||||||||
| Accumulated other comprehensive income | — | 199 | |||||||||
| Total stockholders’ equity | 1,125,382 | 1,094,418 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,336,154 | $ | 1,269,317 | |||||||
Silicon Laboratories Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Nine Months Ended | |||||||||||
| October 3, 2026 | October 4, 2025 | ||||||||||
| Operating Activities | |||||||||||
| Net loss | $ | (17,638) | $ | (62,223) | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation of property and equipment | 18,154 | 18,769 | |||||||||
| Amortization of other intangible assets | 6,884 | 11,074 | |||||||||
| Stock-based compensation expense | 69,754 | 59,645 | |||||||||
| Deferred income taxes | 2,164 | 2,026 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | (15,453) | (12,829) | |||||||||
| Inventories | (37,828) | 23,316 | |||||||||
| Prepaid expenses and other assets | (35,213) | 9,080 | |||||||||
| Accounts payable | 18,373 | 11,141 | |||||||||
| Other current liabilities and income taxes | 3,271 | 29,901 | |||||||||
| Deferred revenue and returns liability | 4,445 | 5,374 | |||||||||
| Other non-current liabilities | 20,285 | (7,916) | |||||||||
| Net cash provided by operating activities | 37,198 | 87,358 | |||||||||
| Investing Activities | |||||||||||
| Purchases of marketable securities | — | (34,790) | |||||||||
| Sales of marketable securities | — | 15,332 | |||||||||
| Maturities of marketable securities | 62,309 | 22,598 | |||||||||
| Purchases of property and equipment | (28,472) | (19,942) | |||||||||
| Proceeds from capital-related government incentives | 8,705 | — | |||||||||
| Purchase of other investment | — | (4,000) | |||||||||
| Net cash provided by (used in) investing activities | 42,542 | (20,802) | |||||||||
| Financing Activities | |||||||||||
| Payment of taxes withheld for vested stock awards | (28,710) | (14,907) | |||||||||
| Proceeds from the issuance of common stock | 7,761 | 8,147 | |||||||||
| Net cash used in financing activities | (20,949) | (6,760) | |||||||||
| Increase in cash and cash equivalents | 58,791 | 59,796 | |||||||||
| Cash and cash equivalents at beginning of period | 364,222 | 281,607 | |||||||||
| Cash and cash equivalents at end of period | $ | 423,013 | $ | 341,403 | |||||||